Back to top

immuno-therapy: Archive

Zacks Equity Research

Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq

The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.

NVSNegative Net Change RHHBYNegative Net Change LLYNegative Net Change

Zacks Equity Research

FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis

With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.

JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change